diagnostics

British diagnostics developer Mologic announced Monday that it plans to transform from a for-profit company into a social enterprise through an acquisition worth at least $41 million. The Soros Economic Development Fund is leading the takeover with support from the Gates Foundation, according to Mologic’s press release.

Under a new name—Global Access Health—the firm aims to expand affordable access to medical technology in LMICs, including tests for diseases such as bilharzia, Covid-…

The state of the fight: 

Gavi inked a 550-million-dose supply deal with China’s CNBG and Sinovac.
  Bharat Biotech applied for WHO Emergency Use Listing of its inactivated vaccine.
  Cuba authorized BioFarmaCuba’s Abdala vaccine.

 

Approved or authorized vaccines

The U.S. FDA granted Priority Review to Pfizer/BioNTech’s Comirnaty vaccine in the companies’ bid for full licensure, the companies announced Friday.
 
While the press release noted a…

France’s bioMérieux and Specific Diagnostics announced Tuesday that bioMérieux will distribute the latter’s newly introduced REVEAL Rapid AST system in Europe.

The deal is a boost to the California-based CARB-X grantee’s antibiotic susceptibility testing (AST) system, designed to quickly detect the emitted volatile molecules that are the first sign of bacterial growth in the blood and to determine which antibiotic is most suited to kill the bacteria.

The press release noted…

San Diego-based Qpex Biopharma announced last week that it has begun a Phase 1 study of QPX9003, its next-generation intravenously administered synthetic polymyxin for infections caused by drug-resistant gram-negative pathogens (including Acinetobacter species and P. aeruginosa).

In other AMR news, the U.S. National Institutes of Health has awarded HelixBind $3.3 million to support testing of its RaPID/BSI diagnostic platform for sepsis-related bloodstream infections, the biotech…

Portland-based Hemex Health announced Monday a software-based upgrade that expands the age range for sickle cell disease (SCD) tests on its portable, low-cost Gazelle platform from 6 months and up to all ages, including newborns.

In other SCD news, San Francisco’s Global Blood Therapeutics said Monday that voxelotor—its oral, once-daily treatment for the disease—has notched Promising Innovative Medicine designation from British regulators.

Mentions:

Boston University-led nonprofit CARB-X announced Tuesday that it will give Arizona-based Accelerate Diagnostics $578,000 (plus up to $2.1 million in milestones) to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections.

In other antimicrobial resistance news, Boston’s Selux Diagnostics announced Tuesday an additional $14.6 million award from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid…

Japan’s Global Health Innovative Technology (GHIT) Fund on Tuesday announced $8.8 million in drug and diagnostic development investments for neglected tropical diseases.

Two awards will support new projects for separate Buruli ulcer and Chagas disease tests. Meanwhile, two additional awards will fund new partnerships between the Drugs for Neglected Diseases Initiative and Japanese partners for leishmaniasis drug discovery and development.

GHIT Fund’s portfolio now includes 61…

Boston University-led CARB-X announced Monday that it will give Australian diagnostics specialist SpeeDx up to $1.8 million (plus up to $1.9 million in milestones) to develop a one-hour combination test for chlamydia and gonorrhea that also determines the susceptibility of gonorrhea infections to common antibiotics. SpeeDX plans to combine its test with a portable, battery-operated device from Britain’s QuantuMDx, making the diagnostic ready for “remote or low-resource settings around the…

Boston University-led CARB-X announced Tuesday that it will give British diagnostics company GenomeKey $3 million (plus up to $6.5 million in milestones) to develop a four-hour test for sepsis. The diagnostic uses machine learning to identify bacterial species and test for antibiotic sensitivity, allowing clinicians to prescribe targeted drugs quickly and “reduce unnecessary antibiotic consumption,” the press release said.

Meanwhile, Massachusetts-based biotech X-Biotix announced…

Funders made new investments in antibiotics, diagnostics and bacteriophage drugs in recent days.

Boston University-led CARB-X announced two new awards. On Monday, the nonprofit said it would give Britain’s Phico Therapeutics up to $5.3 million (plus up to $12.9 million in milestones) to develop a new intravenous engineered bacteriophage drug to treat ventilator-associated pneumonia caused by P. aeruginosa. On Tuesday, CARB-X announced an award of up to $3.9 million (plus up to $7.7…